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Abstract
The use of ATG as part of the reduced-intensity conditioning regimen for AML
is still controversial especially in the setting of matched related donor (MRD)
allogeneic hematopoietic stem cell transplantation (alloHSCT). A previous
study suggested that the use of ATG reduced the incidence of graft versus
host disease (GVHD) but increased the risk of relapse when a MRD is used,
leading to worse outcome compared to patients who did not receive any in
vivo T-cell depletion (CIBMTR data, Soiffer et al., Blood 2011). In contrast, the
EBMT series, focused on AML patients undergoing alloHSCT from MRD in
CR1, showed that the use of ATG reduced the incidence of GVHD without
increasing the risk of relapse (Baron et al., BMT 2014). These discordant
conclusions could be explained by the different median doses of ATG used, 7
and 5 mg/kg in the CIBMTR and EBMT studies, respectively. Thus, we
hypothesized that the dose and the type of ATG are critical issues and could
be a major determinant of outcome after alloHSCT. Here, we investigated the
impact of ATG (Thymoglobulin) dose on cumulative incidences of GVHD, non-
relapse mortality (NRM), relapse (CIR), leukemia-free (LFS) and overall survival
(OS).
Data of patients with the following criteria were collected from the EBMT
registry: alloHSCT between January 2000 and February 2013; AML in CR1;
peripheral blood stem cells from MRD as graft source; RIC regimen; use of
ATG (Thymoglobulin) as part of the RIC regimen.
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We analyzed 334 consecutive patients with a median age of 56 years (range,
19-70). Fifty-eight (17%) patients had unfavorable cytogenetics and 238 (71%)
received a busulfan-based RIC regimen. Most patients (95%) received
cyclosporine A as GVHD prophylaxis, while mycophenolate mophetil (MMF)
was added to 99 patients (30%). ATG was given at the dose of 6 mg/kg or
more (high dose group, median dose: 7.5 mg/kg, range: 6-10.5) in 71
patients (21%) while 263 patients (79%) received less than 6 mg/kg total dose
(low dose group, median dose: 5 mg/kg, range: 2-5.5). Patients in the higher
dose group were more frequently transplanted before 2009, received more
frequently a RIC regimen without busulfan and were more frequently given
MMF in GVHD prophylaxis. Age, time from diagnosis to alloHSCT and
cytogenetic risk groups were equally distributed according to both high and
low ATG dose groups.
In multivariate analysis after adjustment for age (<=55 vs. >55 years),
transplant period (2000-08 vs. 2009-13), cytogenetics (unfavorable vs. other),
RIC regimen (busulfan-based vs. other) and GVHD prophylaxis (MMF vs. no
MMF) showed no significant impact of high ATG dose (low dose was
considered as the reference group) on the incidence of both grade II-IV acute
(OR=0.996 [95%CI, 0.561-1.767]; p=0.989) and chronic GVHD (HR=0.977
[95%CI, 0.543-1.759]; p=0.939). Similarly, ATG dose did not influence the
cumulative incidence of NRM (HR=1.202 [95%CI, 0.467-3.093]; p=0.703).
With a median follow up of 36 months, high ATG dose significantly increased
the CIR (HR=2.298 [95%CI, 1.328-3.977]; p=0.003, Figure A), leading to
significantly shorter both leukemia-free (HR=1.904 [95%CI, 1.186-3.058];
p=0.008) and overall survival (HR=1.711 [95%CI, 1.030-2.844]; p=0.038,
Figure B).
In conclusion, these results suggest that ATG dose is a determinant factor for
outcome. ATG total dose below 6 mg/kg is likely sufficient for GVHD
prophylaxis, with no additional benefit for using the higher ATG doses. In
contrast, a higher ATG dose (6 mg/kg and more) will likely impair outcome of
patients due to a significant increase of the relapse risk. Therefore, in the
setting of CR1 AML patients undergoing RIC alloHSCT from MRD, lower ATG
doses (<6 mg/kg total dose) could be safely used and can allow for better
GVHD control without impairing the overall outcome. These results may differ
in patients transplanted for other diseases than CR1 AML. Further
comparative prospective studies could be helpful to better identify the
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